Product image of Icatibant Stada (Icatibant) supplied by GNH India

Icatibant Stada

Active Ingredient:
Icatibant
Origin:
EU

Icatibant Stada (Icatibant)

Icatibant, the active ingredient in Icatibant Stada, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with confirmed diagnosis.

GNH India supplies Icatibant Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for global distribution, ensuring reliable delivery across multiple continents.

Manufacturer / TM Owner

Stada M&d S.R.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Icatibant is used to treat conditions driven by excessive bradykinin activity, primarily hereditary angioedema.

  • Hereditary angioedema type I: rapid relief of swelling during acute attacks.
  • Hereditary angioedema type II: rapid relief of swelling during acute attacks.
  • Hereditary angioedema with normal C1‑inhibitor: rapid relief of swelling during acute attacks.

How It Works

  • Icatibant acts as a competitive antagonist at the bradykinin B2 receptor, binding to the receptor site and preventing bradykinin from initiating its vasodilatory and permeability‑increasing cascade. By blocking this pathway, the drug reduces the excessive vascular leakage and tissue swelling that characterize hereditary angioedema attacks.

Side Effects

Icatibant may cause a range of adverse reactions following subcutaneous administration.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or erythema: localized skin reddening.
  • Nausea: occasional feeling of queasiness.
  • Headache: transient head discomfort.
  • Dizziness: brief episodes of light‑headedness.
  • Swelling at injection site: mild localized edema.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Urticaria: widespread hives or skin rash.
  • Angioedema of other sites: unexpected swelling of lips, tongue, or airway.
  • Hypotension: sudden drop in blood pressure.
  • Severe injection‑site necrosis: tissue death at the injection area.
  • Hypersensitivity reactions: fever, chills, or systemic rash.

Precautions & Warnings

Before using Icatibant, consider the following safety measures.

  • Pregnancy: safety not established; use only if potential benefit justifies the risk.
  • Breastfeeding: unknown excretion; weigh benefits against possible infant exposure.
  • Renal impairment: no dosage adjustment required, but monitor renal function.
  • Concomitant ACE inhibitors: may increase bradykinin levels; observe for angioedema.
  • Estrogen‑containing therapies: may affect HAE severity; monitor clinical response.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Icatibant can interact with other medicines that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid)

  • ACE inhibitors: additive bradykinin effects may raise angioedema risk.
  • Angiotensin receptor blockers: similar potential for increased bradykinin‑mediated reactions.
  • Other bradykinin B2 antagonists: no added therapeutic benefit and may increase adverse events.

Moderate Interactions (Monitor Closely)

  • Estrogen‑containing contraceptives: may modify HAE attack frequency.
  • Diuretics: monitor fluid balance and blood pressure.
  • Immunosuppressants: observe for heightened infection susceptibility.

Frequently Asked Questions

Icatibant Stada is indicated for the treatment of acute hereditary angioedema (HAE) attacks in patients with confirmed HAE. It works by rapidly reducing swelling and pain associated with these episodes, providing relief when administered at the onset of an attack.

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By binding to this receptor, it blocks bradykinin‑mediated vasodilation and increased vascular permeability, which are key drivers of the swelling seen in hereditary angioedema.

The dose of Icatibant is determined by the prescribing healthcare professional. Typically, a single subcutaneous injection is given at the onset of an HAE attack, with additional doses allowed if the attack persists, as directed by the clinician.

Safety data for Icatibant in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Icatibant Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and the necessary import documentation.

The primary alternative for HAE attacks is plasma‑derived or recombinant C1‑esterase inhibitor therapy. Icatibant offers a subcutaneous, self‑administered option that directly blocks bradykinin, whereas C1‑esterase inhibitors replace the deficient protein. Choice depends on patient preference, attack severity, and clinical response.

Icatibant should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to no more than 30 °C for a short period.

Icatibant is administered by subcutaneous injection, usually into the abdomen or thigh. The injection site should be cleaned with an alcohol swab, and the needle inserted at a 45‑90° angle. Patients are often trained to self‑inject at the first sign of an HAE attack.

Serious risks include anaphylaxis, severe hypersensitivity reactions, and angioedema of the airway or other non‑target sites. If any signs of severe allergic reaction, difficulty breathing, or rapid swelling occur, seek emergency medical care immediately.

Icatibant is contraindicated in individuals with known hypersensitivity to the active substance or any of the excipients. Caution is also advised for patients with a history of severe allergic reactions to other bradykinin‑targeting agents.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Icatibant

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT